Runt-related transcription factor-3 (Runx3) is a tumor suppressor, and its contribution to melanoma progression remains unclear. According to this recent study, self-entrapping of metastatic Runx3-negative melanoma cells via adhesion and the actin cytoskeleton could be a powerful therapeutic strategy.
According to to this recent study, deep learning for dermatologist-level detection of suspicious pigmented skin lesions from wide-field images could allow for rapid and accurate assessments of pigmented lesion suspiciousness within a primary care visit. It could also enable improved patient triaging, utilization of resources, and earlier treatment of melanoma.
According to this recent study, metformin is associated with decreased risk of basal cell carcinoma (BCC)development, even at low doses. Metformin might have potential as a chemoprotective agent for patients at high risk of BCC, although this will need confirmation in future studies.
Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence-free survival for node-positive melanoma in the adjuvant setting and are the focus of this review.
According to this recent study, urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group. Based on the results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence.
According to this recent study, proteomes of tumour‐derived small extracellular vesicles in patients’ plasma discriminate cancer from non‐cancer and identify proteins with potential to serve as prognostic biomarkers in melanoma.
According to this recent study, a better comprehension of the SPANX-A/D protein subfamily and its molecular mechanisms will help to describe new aspects of tumour cell biology and develop new therapeutic targets and tumour-directed pharmacological drugs for skin tumours.
This study aimed to evaluate whether baseline circulating tumour DNA (ctDNA) concentrations and kinetics could predict survival outcomes in melanoma patients. It concludes that retreatment and on-treatment BRAFV600-mutant ctDNA measurements could serve as independent, predictive biomarkers of clinical outcome with targeted therapy.
According to this recent study, LC3B can serve as a predictive biomarker of checkpoint inhibitor blockade to guide patient selection, as well as G9a inhibition as a strategy to extend the proportion of melanoma patients responding to immunotherapy.
This recent study identified several preoperative peripheral inflammatory markers as indicators for poor prognosis in melanoma patients with brain metastases undergoing neurosurgical treatment. Elevated initial C-reactive proteinvalues, higher neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio, and lower lymphocyte-to-monocyte ratio were associated with reduced overall survival.